1 citations,
April 2012 in “Daehan namseong gwahag hoeji” Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
97 citations,
April 2016 in “Andrology” Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.
1 citations,
December 2018 in “Journal of Cosmetic Dermatology” Men with thinner hair from genetic hair loss may be more likely to have an enlarged prostate.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
2 citations,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
125 citations,
January 1999 in “Drugs” Finasteride effectively treats baldness but may cause sexual side effects.
109 citations,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
21 citations,
April 1998 in “Urology” Finasteride effectively treats BPH and hair loss but may cause sexual side effects.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
1 citations,
November 2016 in “Journal of the Dermatology Nurses’ Association” Finasteride treats hair loss but may cause side effects like low libido and dizziness.
1054 citations,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
3 citations,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
11 citations,
January 1995 in “Biomedicine & pharmacotherapy” TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
211 citations,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively treats BPH, but needs more trials to understand potential.
52 citations,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
77 citations,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
65 citations,
March 1999 in “Urology” Finasteride didn't significantly improve ICPPS symptoms, more research needed.
1 citations,
May 2017 in “Urologe A” Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.
12 citations,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
33 citations,
October 2004 in “Archives of Dermatological Research” Large prostate links to more hair loss, but age of onset doesn't affect it.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
49 citations,
August 2009 in “British Journal of Cancer” Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.
44 citations,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
14 citations,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
4 citations,
November 2005 in “The Journal of Urology” Large prostates link to more hair loss.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
April 2012 in “The Journal of Urology” Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.